Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Developmental Disorder Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NIPBL drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NIPBL Recombinant Protein (MAU2-Binding Domain / HEAT Repeats) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for interaction assays. |
View NIPBL Products |
| Gene Delivery | NIPBL Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and localization studies. |
View NIPBL Products |
| Benchmark Ab | Anti-NIPBL Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP. |
View NIPBL Products |
| Validator | NIPBL siRNA Set Target-specific knockdown verification in functional assays. |
View NIPBL Products |
| Related Target A | MAU2 Obligate binding partner forming the active cohesin-loading complex with NIPBL. |
View MAU2 Products |
| Related Target B | RAD21 Core cohesin subunit; critical downstream effector of NIPBL-mediated loading. |
View RAD21 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| NIPBL-MAU2 complex reconstitution | Co-expressed or highly purified individual subunit domains with verified sequence identity. |
| Assay specificity in high-throughput screening | Strictly quality-controlled recombinant proteins with >95% purity determined by SDS-PAGE. |
| Lack of Controls | High-affinity benchmark antibodies included for assay validation. |
| False Positives | Validated siRNA pools included for target-specific knockdown control. |
Live NIPBL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NIPBL therapeutics is intensifying, with major players shifting focus from traditional gene regulation models to targeted protein degradation (PROTACs) and synthetic lethality screening in STAG2-deficient cancers. As first-generation therapies targeting the cohesin complex reach the preclinical-to-clinical transition, the next wave of R&&D is targeting the specific protein-protein interaction (PPI) interface between NIPBL and MAU2 to modulate chromosome loop extrusion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | STAG2-Mutant Cancers, Ewing Sarcoma | In vitro binding assays (Need high-purity NIPBL/MAU2 domains) |
| PROTACs / Degraders | Targeted Protein Degradation Pioneers | Acute Myeloid Leukemia (AML), Solid Tumors | Degradation kinetics (Need Lentivirus for GFP-NIPBL stable lines) |
| Gene Therapy / mRNA | Rare Disease Therapeutics Consortia | Cornelia de Lange Syndrome (CdLS) | Expression rescue validation (Need sequence-verified ORF/Lentivirus) |